Dermapharm Holding SE (CHIX:DMPD) Price-to-Tangible-Book: (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €44.50
! 5 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Price-to-Tangible-Book?

As of today (2026-09-01), Dermapharm Holding SE's share price is €46.175. Dermapharm Holding SE's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was €-10.95. Hence, Dermapharm Holding SE's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Dermapharm Holding SE's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Dermapharm Holding SE's highest Price to Tangible Book Ratio was 152.52. The lowest was 152.52. And the median was 152.52.

CHIX:DMPd's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.33
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Dermapharm Holding SE's share price is €46.175. Dermapharm Holding SE's Book Value per Sharefor the quarter that ended in Jun. 2026 was €10.83. Hence, Dermapharm Holding SE's P/B Ratio of today is 4.26.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Dermapharm Holding SE Price-to-Tangible-Book Related Terms


Dermapharm Holding SE Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Price-to-Tangible-Book Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dermapharm Holding SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CHIX:DMPD vs ZTS, UTHR, VTRS: Price-to-Tangible-Book Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE Price-to-Tangible-Book vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Price-to-Tangible-Book falls into.


CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Price-to-Tangible-Book Calculation

Dermapharm Holding SE's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2026 )
=46.175/-10.946
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 3.8% above its estimated GF Value™ of €44.50.

Key valuation signals for CHIX:DMPD:

  • Price-to-Tangible-Book:
  • GF Value™: €44.50 vs. price of €46.18 (3.8% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€44.50
GF Value